Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.37 |
| ▸ | GAA | P10253 | 8/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | GLA | P06280 | 5/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2644532 | 1.00 | ALDH1A1 (0.37) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2643933 | 0.83 | TSHR (0.43) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2644471 | 0.80 | KDM4E (0.35) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2644915 | 0.79 | GCK (0.36) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL644027 | 0.79 | GCK (0.58) | GCKNPC1 | |
| SCHEMBL2644213 | 0.79 | IRAK4 (0.39) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2643997 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL643590 | 0.78 | MAOB (0.49) | HPGDNPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL642767 | 0.78 | MAPT (0.41) | ALDH1A1KDM4EGAAHPGDGLA | |
| SCHEMBL2644681 | 0.76 | GCK (0.39) | ALDH1A1KDM4EGAAHPGDGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | ALDH1A1 1370/4885KDM4E 1790/4885GAA 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.